Cancer immunotherapy targets and eliminates cancer cells by artificial stimulation boosting the body's immune system.
Numerous novel strategies, besides adoptive cell therapies, are in development and in clinical practice thanks to their ability to ensure durable clinical response : oncolytic viruses, monoclonal antibodies, cancer vaccines, checkpoint inhibitors.
The fill & finish step, conventionally associated with contamination risks, is particularly impacted, due to the high value of the product at this step.
Fast process development, manufacturing deployment and it’s further efficient scalability from Phase I to commercial is essential for cancer immunotherapies, to reduce time-to-market and bring the products to the patients.
Discover how our scalable fill & finish machines bring strength to the manufacturing roadmap of cancer immunotherapies globally, while cutting the validation cost.